Prulifloxacin

Drugs

Volumn 64, Issue 19, 2004, Pages 2221-2234

  Keam, Susan J ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE; CIMETIDINE; CIPROFLOXACIN; COAGULASE; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTERASE; FENBUFEN; GENTAMICIN; LEVOFLOXACIN; METICILLIN; MOXIFLOXACIN; NALIDIXIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; OXACILLIN; PEFLOXACIN; PENICILLIN DERIVATIVE; PLASMA PROTEIN; PRODRUG; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; TROVAFLOXACIN; ULIFLOXACIN; UNCLASSIFIED DRUG; UNIDROX; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONVULSION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; HEART ARRHYTHMIA; HUMAN; IN VITRO STUDY; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORGANELLA; NAUSEA; NONHUMAN; PHOTOTOXICITY; PROTEUS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RASH; REVIEW; SINGLE DRUG DOSE; STOMACH DISEASE; STOMACH PAIN; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; CIPROFLOXACIN; CLAVULANIC ACID; DIOXOLANES; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HALF-LIFE; HUMANS; ITALY; MOLECULAR STRUCTURE; NEW ZEALAND; PIPERAZINES; PRODRUGS; QUINOLONES; URINARY TRACT INFECTIONS;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ESCHERICHIA COLI; HAEMOPHILUS; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; NEGIBACTERIA; POSIBACTERIA; PROVIDENCIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 6044275650     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464190-00005     Document Type: Review

References (46)

1. Ozaki M, Matsuda M, Tomii Y, et al. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob Agents Chemother 1991 Dec; 35 (12): 2496-9
2. Hooper D. Mode of action of fluoroquinolones. Drugs 1999; 58 Suppl. 2; 6-10
3. Angelini ACRAF S.p.A. Investigator's brochure: Unidrox® prulifloxacin 600mg tablets. Rome: ACRAF S.p.A., 2004 Apr 20. (Data on file)
4. Grassi C, Salvatori E, Rosignoli MT, et al. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbation of chronic bronchitis. Respiration 2002; 69 (3): 217-22
5. Grossman RF. Guidelines for the treatment of acute exacerbation of chronic bronchitis. Chest 1997; 112 Suppl.: 310S-3S
6. Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbation of chronic bronchitis: Canadian Thoracic Society and the Canadian Infectious Disease Society. Can Respir J 2003; 10 Suppl. B: 3B-32B
7. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001 Jun; 163 (7): 1730-54
8. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000 May 22; 160 (10): 1399-408
9. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33
10. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women: Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999 Oct; 29 (4): 745-58
11. Hooten TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents 2003; 22 Suppl.: S65-72
12. Naber KG, Bergman B, Bishop MC, et al. EAU guidelines for the management of urinary and male genital tract infections: Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001; 40: 576-88
13. Melekos MD, Naber KG. Complicated urinary tract infections. Int J Antimicrob Agents 2000; 15: 247-56
14. Montanari MP, Mingoia M, Varaldo PE. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemother 2001 Dec; 45 (12): 3616-22
15. Prats G, Roig C, Miro E, et al. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones [published erratum appears in Eur J Clin Microbiol Infect Dis 2004; 23: 422]. Eur J Clin Microbiol Infect Dis 2002 Apr; 21 (4): 328-34
16. Prats G, Roig C, Miro E, et al. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones [published erratum appears in Eur J Clin Microbiol Infect Dis 2004; 23: 422]. Eur J Clin Microbiol Infect Dis 2002 Apr; 21 (4): 328-34
17. Yoshida T, Mitsuhashi S. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother 1993 Apr; 37 (4): 793-800
18. Tomii Y, Sumumura N, Kitamura J. Comparison of NM394 with other drugs in antibacterial activity against quinolone-resistant bacteria. Kyoto: Nippon Shinyaku Co. Ltd, 1996 Nov 11. (Data on file)
19. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. 5th ed. Wayne (PA): National Committee for Clinical Laboratory Standards, 2000
20. National Committee for Clinical Laboratory Standards. MIC testing supplemental tables. M100-S10 (M7). Wayne (PA): National Committee for Clinical Laboratory Standards, 2000
21. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: fourteenth informational supplement M100-S14. Wayne (PA): National Committee for Clinical Laboratory Standards, 2004
22. Nishino T, Tomii Y, Shibata K, et al. In vitro and in vivo antibacterial activity of NM441 [in Japanese]. Jpn J Chemother 1996; 44 Suppl. 1: 56-69
23. Tomii Y, Ozaki M, Matsuda M, et al. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Arzneimittelforschung 1996; 46 (II): 1169-73
24. Lacroix P, Crumb WJ, Durando L, et al. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur J Pharmacol 2003 Sep 5; 477 (1): 69-72
25. Akita M, Shibazaki Y, Izumi M, et al. Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 2004 Feb; 29 (1): 63-71
26. Ukai Y, Yamazaki A, Kurosaka C, et al. Convulsant effects of NM441, a prodrug type antibacterial agent of the quinolone class [in Japanese]. Jpn J Chemother 1996; 44 Suppl. 1: 102-12
27. Picollo R, Brion N, Gualano V, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneim.-Forsch./Drug Res 2003; 53 (3): 201-5
28. Fattore C, Cipolla G, Gatti G, et al. Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers. Clin Drug Invest 1998 Nov; 16 (5): 387-92
29. Totsuka K, Kikuchi K, Shimizu K. Pharmacokinetics in concomitant administration with probenecid and clinical study of NM441 [in Japanese]. Jpn J Chemother 1996; 44 Suppl. 1: 279-88
30. Shiba K, Yoshida M, Sakai O, et al. Pharmacokinetics and clinical studies on NM441 [in Japanese]. Jpn J Chemother 1996; 44 Suppl. 1: 263-78
31. Saito A, Tarao F. Influence of milk on absorption of NM441, a prodrug type of quinolone antibiotic [in Japanese]. Jpn J Chemother 1996; 44 Suppl. 1: 221-8
32. Mignot A, Millerioux L, Berland C, et al. A repeat dose study of NM441 in healthy volunteers. Rome: Angelini Ricerche S.p.A., 2001 May 7. (Data on file)
33. Villa G, Olivieri L, Picollo R, et al. Safety, tolerability and pharmacokinetic evaluation of prulifloxacin (AF3012) 600mg single dose in patients with mild or moderate renal impairment. Rome: Angelini Ricerche S.p.A., 1998 Aug 28. (Data on file)
34. Tullio V, Cuffini AM, Bonino A, et al. Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin. J Antimicrob Chemother 2000 Aug; 46 (2): 241-7
35. Tullio V, Cuffini AM, Bonino A, et al. Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae. Drugs Exptl Clin Res 1999; XXV (1): 1-11
36. Ozaki M, Komori K, Matsuda M, et al. Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1996 Mar; 40 (3): 739-42
37. Tougou K, Nakamura A, Watanabe S, et al. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998 Apr; 26 (4): 355-9
38. Gialdroni Grassi G. Prulifloxacin [abstract], Attualità e Controversie in Terapia Antinfettiva; 2000 Mar 22-25; Verona
39. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996 Jun; 51 (6): 1019-74
40. Zagni R, Orticelli G, Rosignoli MT, et al. Double-blind, controlled study of prulifloxacin in comparison with ciprofloxacin in the treatment of acute uncomplicated lower urinary tract infections. Rome; Angelini Ricerche S.p.A., 1998 Jun 27. (Data on file)
41. Carmignani G, Caranti S, Rosignoli MT, et al. Double blind ciprofloxacin controlled study of prulifloxacin in the treatment of complicated lower urinary tract infections. Rome: Angelini Ricerche S.p.A., 1998 Jul 15. (Data on file)
42. Grassi C, Salvatori E, Martini A, et al. Evaluation of efficacy and tolerability of prulifloxacin versus amoxi-clavulanic acid in the treatment of acute exacerbations of chronic bronchitis. Rome: Angelini Ricerche S.p.A., 1998 May 27. (Data on file)
43. Cervigni M, Orticelli G, Bologna M, et al. Single-dose prulifloxacin versus single-dose pefloxacin in the treatment of acute uncomplicated urinary tract infection in women. Urogynaecol Int 2003; 17 (2): 69-77
44. Defidio L, Olivieri L, Rosignoli MT, et al. Efficacy and tolerability of prulifloxacin versus amoxi-clavulanic acid in the treatment of complicated urinary tract infections. Rome: Angelini Ricerche S.p.A., 1998 May 27. (Data on file)
45. Prulifloxacin approved in Japan. Scrip 2002 Oct 16; (2790): 22
46. Prulifloxacin. NAD-441A, NM 441, Quisnon. Drugs R D 2002; 3 (6): 426-30